^
    11d
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=72, Recruiting, Zhejiang University | N=44 --> 72
    Enrollment change
    |
    GPC3 (Glypican 3)
    |
    Imfinzi (durvalumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • AZD7003
    18d
    A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=121, Recruiting, Shanghai AbelZeta Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD7003
    18d
    GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma (clinicaltrials.gov)
    P1, N=27, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting | Trial completion date: Jun 2044 --> Dec 2044 | Initiation date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jun 2029 --> Dec 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    21d
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Seattle Children's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma. (PubMed, Gastroenterol Rep (Oxf))
    In addition, plasma proteins were significantly associated with survival outcomes, whereas no significant association was observed between clinical variables and prognosis. Plasma proteomics not only captured CAR-GPC3-driven plasma microenvironment remodeling but also identified baseline proteins predictive of CB and survival, which were superior to clinical variables, thus constituting a candidate biomarker panel for HCC patient selection and response monitoring.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • GPC3 (Glypican 3)
    |
    CT0180
    2ms
    DUET-1: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Sotio Biotech Inc. | Trial primary completion date: Oct 2027 --> Oct 2025
    Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation
    |
    cyclophosphamide • BOXR1030
    2ms
    Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=24, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • fludarabine IV
    2ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
    Enrollment change
    |
    GPC3 (Glypican 3) • IL15 (Interleukin 15)
    |
    AGAR T cells
    3ms
    INTERCEPT: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    3ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
    Enrollment closed • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    4ms
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Zhejiang University | Trial completion date: Jun 2024 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • GPC3 (Glypican 3)
    |
    cyclophosphamide • CT0180
    5ms
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial